A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects

Clinical Pharmacokinetics

Volumn 51, Issue 10, 2012, Pages 681-693

  Dockens, Randy ^a   Wang, Jun Sheng ^a   Castaneda, Lorna ^a   Sverdlov, Oleksandr ^a   Huang, Shu Pang ^a   Slemmon, Randy ^a   Gu, Huidong ^a   Wong, Oi ^a   Li, Hewei ^a   Berman, Robert M ^a   Smith, Christina ^a   Albright, Charles F ^a   Tong, Gary ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; GLYCOPROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CEREBROSPINAL FLUID LEVEL; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUSP6 GENE; EPISTAXIS; FEMALE; FLATULENCE; GENE; GENE EXPRESSION; HEADACHE; HES 1 GENE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE DRUG DOSE; NORMAL HUMAN; OCCULT BLOOD TEST; OROPHARYNX PAIN; ORTHOSTATIC HYPOTENSION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TFF3 GENE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGING; AMYLOID PRECURSOR PROTEIN SECRETASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; SEX FACTORS; SULFONAMIDES; TIME FACTORS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84872320528     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0005-x     Document Type: Article

References (27)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2010;6(2):158-94.
2. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115:1121-9.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-6.
4. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem. 2009;110:1129-34.
5. Walsh DM, Selkoe DJ. A beta oligomers: a decade of discovery. J Neurochem. 2007;101:1172-84.
6. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28:126-32.
7. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009;331:598-608.
8. Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, et al. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem. 2008;283:22992-3003.
9. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther. 2006;319:924-33.
10. Guardia-Laguarta C, Pera M, Lleo A. Gamma-secretase as a therapeutic target in Alzheimer's disease. Curr Drug Targets. 2010;11:506-17.
11. Weerkamp F, Luis TC, Naber BA, Koster EE, Jeannotte L, van Dongen JJ, et al. Identification of Notch target genes in uncommitted T-cell progenitors: no direct induction of a T-cell specific gene program. Leukemia. 2006;20:1967-77.
12. Wright NA, Hoffmann W, Otto WR, Rio MC, Thim L. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett. 1997;408:121-3.
13. Gillman KW, Starett JJE, Parker MF. Discovery and evaluation of BMS-708163, a potent, selective, and orally bioavailable gamma secretase inhibitor. ACS Med Chem Lett (in press).
14. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920-4.
15. Gu H, Deng Y, Wang J, Aubry AF, Arnold ME. Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2319-26.
16. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis. 2009;16:389-97.
17. Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem. 2002;48:1883-90.
18. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-37.
19. Perrier D, Gibaldi M. General derivation of the equation for time to reach a certain fraction of steady state. J Pharm Sci. 1982;71:474-5.
20. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980;8:509-34.
21. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R, et al. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther. 2012;34:654-67.
22. De Strooper B, Annaert W. Novel research horizons for presenilins and gamma-secretases in cell biology and disease. Annu Rev Cell Dev Biol. 2010;26:235-60.
23. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99-107.
24. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602-4.
25. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol. 2007;30:317-25.
26. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031-8.
27. Salloway S, Coric V, Brody M, Andreasen N, van Dyck C, Soininen H, et al. Safety and tolerability of BMS-708163 in a phase II study in mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2011;7:6-7.